Author’s response to reviews

Title: Metastasis of a Caecal Adenocarcinoma to the Prostate 5 years after a Right Hemi-colectomy: A Case Report

Authors:

Fady R Youssef MBChB, BSc, MRCS (Ed) (fyoussef@gmail.com)
Leanne Hunt MBChB (lhtig@aol.com)
Pieter D Meiring MBChB, FRCR (pieter.meiring@chesterfieldroyal.nhs.uk)
Danesh R Taraporewalla MBChB, FRC(Path)
(danesh.taraporewalla@chesterfieldroyal.nhs.uk)
Robin Gupta NSc, MBBS, FRCSEd, FRCS(Gen Surg)
(robin.gupta@chesterfieldroyal.nhs.uk)
Mike J James MBChB, BSc, FRCS(Ed), DM, FRCS(Urol)
(Mike.James@chesterfieldroyal.nhs.uk)

Version: 3 Date: 16 November 2010

Author’s response to reviews: see over
Dear Prof Michael Kidd, Editor-in-Chief,

I respectfully request the publication of this extremely rare case. It involves a rare presentation of an isolated prostatic metastasis from a primary caecal adenocarcinoma, surgically excised 5 years previously.

As far as I am aware this is the fourth documented case in the literature, and the second documented case where the original primary tumour was from a right sided bowel adenocarcinoma. The other two were sigmoid in origin.

This case is unique where initial immuno-staining was not fully conclusive and a relatively new method of immuno-staining, CDX-2, was used to ascertain its histopathology.

I can confirm that all authors made substantial contributions to either drafting or revising the article and have approved the final version prior to submission.

This case has not previously been published and is currently not for consideration for publication with any other journal.

I am very grateful for your time and effort in considering this for publication.

Yours sincerely

Mr Fady R Youssef
MBChB, BSc, MRCS (Ed)
Urology Registrar, Sheffield, UK.
fyoussef@gmail.com

Ammendment in response to comments:

What is proposed treatment? Radical Pelvic Exenteration

Why radical treatment chosen? Best chance of curative treatment in the absence of distant metastases on PET-CT. Other modalities would not offer this.

QUASAR Trial? Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study

CDX-2? A homeobox gene that encodes an intestine specific transcription factor, expressed in the nuclei of intestinal cells throughout the intestine from duodenum to rectum.